Genentech/Roche presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS)… read more.
Two recent reports show how hard lung cancer outcomes have been impacted as a result of the covid-19 pandemic, according to Professor Robert Rintoul, chair of the UK… read more.
Findings also reveal decline in smoking led to decrease in another type of lung cancer. An international team of scientists, led by Nanyang Technological University, Singapore (NTU Singapore),… read more.
Head and neck cancer survivors with long smoking histories had a 2.5-fold greater risk of developing lung cancer than those without prior head and neck cancer, according to… read more.
Drugs which are already (U.S.) Food and Drug Administration (FDA) approved could be effective in treating of lung cancer in “never-smokers,” researchers reported on Sept. 30, 2021 in… read more.
Genentech/Roche announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab) as adjuvant treatment following surgery and platinum-based… read more.
Cancers are not only made of tumour cells. In fact, as they grow, they develop an entire cellular ecosystem within and around them. This “tumour microenvironment” is made… read more.
Merck announced the company is voluntarily withdrawing the U.S. indication for Keytruda (pembrolizumab) for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression… read more.
Interview and article by Christine Clark. Delayed diagnoses and more patients with advanced cancers were consequences of the coronavirus pandemic, according to Dr Erin Schenk, Assistant Professor, Thoracic… read more.
Interview and article by Christine Clark. Modern lung cancer treatment has changed the outlook for lung cancer patients considerably and interesting trial results are expected this year, according… read more.
Interview and article by Christine Clark. Dr Erin Schenk, Assistant Professor, Thoracic Oncology, University of Colorado describes the results of the ADAURA trial and the implications for her… read more.
Interview and article by Christine Clark IMI interviewed Dr Erin Schenk, Assistant Professor, Thoracic Oncology, University of Colorado to find out about key trial results in lung cancer… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
